Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Rebecca M. Silvola"'
Autor:
Margaret A. Tharp, Rebecca M. Silvola, Claire Marks, Evgennia Teal, Sara K. Quinney, David M. Haas
Publikováno v:
BMC Pregnancy and Childbirth, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background The objective of this study was to determine if the lack of exposure to individual antidepressants at certain times in pregnancy improved maternal and infant outcomes. Methods This was a retrospective cohort study of 2741 pregnant
Externí odkaz:
https://doaj.org/article/4eb42d86d8ab43c180fd645882ee03c2
Autor:
Nicholas R. Powell, Rebecca M. Silvola, John S. Howard, Sunil Badve, Todd C. Skaar, Joseph Ipe
Publikováno v:
Cancer Reports, Vol 6, Iss 1, Pp n/a-n/a (2023)
Abstract Background Chemotherapeutic drug concentrations vary across different regions of tumors and this is thought to be involved in development of chemotherapy resistance. Insufficient drug delivery to some regions of the tumor may be due to spati
Externí odkaz:
https://doaj.org/article/8bf95053c85c4e7b9fec94e8dd3e68d8
Autor:
Jagdeep T. Podichetty, Rebecca M. Silvola, Violeta Rodriguez‐Romero, Richard F. Bergstrom, Majid Vakilynejad, Robert R. Bies, Robert E. Stratford Jr.
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1864-1874 (2021)
Abstract Clinical trial efficiency, defined as facilitating patient enrollment, and reducing the time to reach safety and efficacy decision points, is a critical driving factor for making improvements in therapeutic development. The present work eval
Externí odkaz:
https://doaj.org/article/465bc14d8d9e43dfb47e8832dbded935
Publikováno v:
Pharmacotherapy
OBJECTIVE: To compare associations between individual antidepressants and newborn outcomes. DESIGN: Retrospective cohort study SETTING: Deliveries in a large, US medical system. POPULATION: Women who received at least one antidepressant prescription
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8569623af763bf091b666089c005622b
https://doi.org/10.1002/phar.2628
https://doi.org/10.1002/phar.2628
Publikováno v:
Br J Clin Pharmacol
AIMS Physiologically based pharmacokinetic (PBPK) models have been previously developed for betamethasone and buprenorphine for pregnant women. The goal of this work was to replicate and reassess these models using data from recently completed studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0097e6006a4246c27e06c0fb1521154c
https://doi.org/10.1111/bcp.15018
https://doi.org/10.1111/bcp.15018
Autor:
Nicholas R. Powell, Rebecca M. Silvola, John S. Howard, Sunil Badve, Todd C. Skaar, Joseph Ipe
Publikováno v:
Cancer Reports. 6
Chemotherapeutic drug concentrations vary across different regions of tumors and this is thought to be involved in development of chemotherapy resistance. Insufficient drug delivery to some regions of the tumor may be due to spatial differences in ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af6d56f5e641cfcdf7edafe1c6223bdc
https://doi.org/10.1002/cnr2.1686
https://doi.org/10.1002/cnr2.1686
Autor:
Margaret A. Tharp, Rebecca M. Silvola, Claire Marks, Evgennia Teal, Sara K. Quinney, David M. Haas
Publikováno v:
BMC pregnancy and childbirth. 22(1)
Background The objective of this study was to determine if the lack of exposure to individual antidepressants at certain times in pregnancy improved maternal and infant outcomes. Methods This was a retrospective cohort study of 2741 pregnant women pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7a5169b2d918bba5d70f51b26b22be3
https://pubmed.ncbi.nlm.nih.gov/36482347
https://pubmed.ncbi.nlm.nih.gov/36482347
Autor:
Robert E. Stratford, Richard F. Bergstrom, Jagdeep T. Podichetty, Violeta Rodriguez‐Romero, Rebecca M. Silvola, Robert R. Bies, Majid Vakilynejad
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 5, Pp 1864-1874 (2021)
Clinical and Translational Science, Vol 14, Iss 5, Pp 1864-1874 (2021)
Clinical trial efficiency, defined as facilitating patient enrollment, and reducing the time to reach safety and efficacy decision points, is a critical driving factor for making improvements in therapeutic development. The present work evaluated a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4ce7892ca222a9de20fc8f407b8f5e
https://pubmed.ncbi.nlm.nih.gov/33939284
https://pubmed.ncbi.nlm.nih.gov/33939284